Metagenomi Therapeutics Inc (MGX) - News Archive

The advancement of genome editing tools has transformed the landscape of genetic engineering. At the recent Nature Conference RNA at the Bench and Bedside IV, Metagenomi introduced MGX-001, a cutting-edge gene editing s...

Harnessing Genetic Innovation: Metagenomi s Promising Breakthrough in Hemophilia A Therapy Showcased at ASH 66th Annual Meeting Therapeutically relevant levels of Factor VIII (FVIII) activity sustained in ongoing nonhum...

In the dynamic landscape of biotechnology and drug discovery, the fortunes of companies can shift dramatically, leading to significant implications for investors. A recent wave of legal actions has emerged surrounding M...

: Metagenomi, Inc. has announced that their latest preclinical data regarding hemophilia A, specifically the site-specific insertion of the Factor VIII gene, will be presented at the upcoming American Society of Hematol...

Metagenomi Inc. (NASDAQ: MGX), a rising player in the rapidly evolving biotechnology landscape, finds itself at a crossroads. As the company unveils its groundbreaking SMART Editing Platform at the AIChE 7th Internation...

Navigating Turbulent Waters: The Class Action Storm Facing Metagenomi Inc. In the intricate world of biotechnology, where innovation often meets regulatory and financial scrutiny, Metagenomi Inc. (NASDAQ: MGX) finds its...

Metagenomi, Inc. (NASDAQ: MGX) Faces Legal Scrutiny: Investors Urged to Seek Counsel Amid Financial Losses In recent developments, Metagenomi, Inc. a biotechnology firm listed on Nasdaq under the ticker symbol MGX, has...

Hemophilia A, a genetic disorder characterized by a deficiency in clotting factor VIII (FVIII), poses significant challenges in management and patient quality of life. New therapeutic approaches are urgently needed to a...